Real-Life Vancomycin Therapeutic Drug Monitoring in Coagulase-Negative Staphylococcal Bacteremia in Neonatal and Pediatric Intensive Care Unit: Are We Underestimating Augmented Renal Clearance?
Claudia Sette,
Marcello Mariani,
Luca Grasselli,
Alessio Mesini,
Carolina Saffioti,
Chiara Russo,
Roberto Bandettini,
Andrea Moscatelli,
Luca A. Ramenghi,
Elio Castagnola
Affiliations
Claudia Sette
Department of Pediatrics, Ospedale SS. Annunziata, 74121 Taranto, Italy
Marcello Mariani
Pediatrics and Infectious Diseases Unit, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy
Bloodstream infections (BSI) from coagulase-negative-staphylococci (CoNS) are among the most frequent healthcare-related infections. Their treatment involves the use of vancomycin, a molecule whose optimal pharmacokinetic/pharmacodynamic (PK/PD) target for efficacy and safety is an area-under-curve/minimum inhibitory concentration (AUC/MIC) ratio ≥ 400 with AUC p 2), beyond which it is extremely unlikely to achieve an AUC ≥ 400, and therefore a higher dose or a different antibiotic should be chosen.
